TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17624842

Group type: EXPERIMENTAL
Intervention: Breast milk from HIV-infected women
Number of subjects: 725

Group type: COMPARATOR
Intervention: Breast milk from HIV-uninfected women
Number of subjects: 725

Group type: COMPARATOR
Intervention: Breast milk from HIV-exposed uninfected women
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Discontinuation of breast-feeding
Number of subjects: 725
Study: 17626713

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10, 20, 40, 80 mg/day)
Number of subjects: 610
Study: 17634466

Group type: EXPERIMENTAL
Intervention: Anti-TNF antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 17635942

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg at 10- to 14-wk intervals
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 66
Study: 17637939

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study: 17643576

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 48612

Group type: COMPARATOR
Intervention: No Diabetes Mellitus (nondiabetic patients)
Number of subjects: 48612
Study: 17646603

Group type: EXPERIMENTAL
Intervention: Provision of complete discharge instructions
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Smoking-cessation counseling
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Left ventricular function assessment
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors prescribed at discharge
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Use of preprinted admission order sets and/or discharge checklists
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Mean length of stay
Number of subjects: 48612

Group type: EXPERIMENTAL
Intervention: Trends for reduction of in-hospital mortality, postdischarge death, and combined postdischarge death and rehospitalization
Number of subjects: 48612
Study: 17647221

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (n = 64) with educational materials, 90 minutes once a week for a minimum of 1 year.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control condition (n = 61) with only educational materials for a minimum of 1 year.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy for ER-negative participants.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control for ER-negative participants.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy for ER-positive participants.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control for ER-positive participants.
Number of subjects: 125
Study: 17650319

Group type: EXPERIMENTAL
Intervention: Recombinant human prolactin (r-hPRL)
Number of subjects: 21
Study: 17656603

Group type: EXPERIMENTAL
Intervention: 1-year obesity intervention program
Number of subjects: 133

Group type: COMPARATOR
Intervention: Obese children
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Changes in PTH and 25-OH Vit D
Number of subjects: 133
Study: 17659962

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection (1.25 mg/0.05 ml)
Number of subjects: 3
Study: 17662149

Group type: EXPERIMENTAL
Intervention: Active RA patients
Number of subjects: 17
Study: 17666616

Group type: EXPERIMENTAL
Intervention: Protease inhibitor regimen
Number of subjects: 158

Group type: COMPARATOR
Intervention: No protease inhibitor regimen
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High triglycerides group
Number of subjects: 158
Study: 17673691

Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nonseptic patients with OF
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both patient groups (septic and nonseptic)
Number of subjects: 90
Study: 17679662

Group type: EXPERIMENTAL
Intervention: McDonald's branded foods and beverages
Number of subjects: 63

Group type: COMPARATOR
Intervention: Unbranded foods and beverages
Number of subjects: 63
Study: 17679671

Group type: EXPERIMENTAL
Intervention: Weill Cornell LINCL scale
Number of subjects: 18

Group type: COMPARATOR
Intervention: Modified Hamburg LINCL scale
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MRI measurements
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cortical MRS N-acetyl-aspartate content, MRI ventricular, gray matter and white matter volume, and cortical apparent diffusion coefficient
Number of subjects: 18
Study: 17679729

Group type: EXPERIMENTAL
Intervention: Decitabine alone (20 mg/m(2)/d intravenously for 10 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Decitabine plus valproic acid (VA) (at OBD, days 1 through 10, with dose-escalating VA days 5 through 21)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 17682000

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: White light
Number of subjects: 62
Study: 17684047

Group type: EXPERIMENTAL
Intervention: Standard replacement therapy for adrenal insufficiency
Number of subjects: 256
Study: 17686450

Group type: EXPERIMENTAL
Intervention: One-drug group (prostaglandin analogs)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Two-drug group (prostaglandin analogs plus adjunctive medication)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor antagonists (part of two-drug group)
Number of subjects: 62
Study: 17686822

Group type: EXPERIMENTAL
Intervention: Combination treatment with bevacizumab and chemotherapy
Number of subjects: 1745

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1745

Group type: EXPERIMENTAL
Intervention: Baseline or on-study aspirin use in bevacizumab-treated patients
Number of subjects: 1745

Group type: COMPARATOR
Intervention: Baseline or on-study aspirin use in control subjects
Number of subjects: 1745
Study: 17687130

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²) administered as four weekly infusions
Number of subjects: 21
Study: 17694552

Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha at a dose of 200 microg every 2 weeks
Number of subjects: 2401
Study: 17698748

Group type: EXPERIMENTAL
Intervention: hsUHR-OCT imaging
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional slitlamp biomicroscopy
Number of subjects: 8
Study: 17699416

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 20,000 IU subcutaneously every 2 weeks
Number of subjects: 67
Study: 17700015

Group type: EXPERIMENTAL
Intervention: CVVH with regional citrate anticoagulation (RCA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: CVVH without regional citrate anticoagulation (anticoagulant-free predilution CVVH)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CVVH with RCA
Number of subjects: 51

Group type: COMPARATOR
Intervention: CVVH with RCA and CVVH without RCA
Number of subjects: 51
Study: 17704543

Group type: COMPARATOR
Intervention: Normal blood pressure (120-9/75-84 mm Hg)
Number of subjects: 39322

Group type: EXPERIMENTAL
Intervention: High normal blood pressure (130-9/85-9 mm Hg)
Number of subjects: 39322

Group type: EXPERIMENTAL
Intervention: Baseline hypertension
Number of subjects: 39322

Group type: EXPERIMENTAL
Intervention: Progression to hypertension
Number of subjects: 39322

Group type: EXPERIMENTAL
Intervention: High normal blood pressure who progressed to hypertension
Number of subjects: 39322
Study: 17705950

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study: 17707182

Group type: EXPERIMENTAL
Intervention: Heart failure with preserved systolic function (PSF) (EF > or =40%)
Number of subjects: 21149

Group type: EXPERIMENTAL
Intervention: Discharge use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or beta-blocker
Number of subjects: 21149
Study: 17709602

Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg daily) dose de-escalation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Reinitiation of therapy at prior effective dose
Number of subjects: 5

Group type: COMPARATOR
Intervention: Imatinib (300 to 400 mg daily)
Number of subjects: 5
Study: 17709827

Group type: EXPERIMENTAL
Intervention: Bevacizumab alone (cycle 1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (cycles 2-7)
Number of subjects: 19
Study: 17713466

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 176
Study: 17715389

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg orally twice daily
Number of subjects: 280
Study: 17717136

Group type: EXPERIMENTAL
Intervention: Valproate (VPA), a histone deacetylase inhibitor, used as a chronic treatment for epileptic disorders.
Number of subjects: 0
Study: 17717285

Group type: EXPERIMENTAL
Intervention: Flexible intensive insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 0
Study: 17718658

Group type: EXPERIMENTAL
Intervention: Case Management (CM) plus primary care
Number of subjects: 419
Study: 17723147

Group type: EXPERIMENTAL
Intervention: ORAL IMPACT (immunonutrient formula)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up for 12 weeks
Number of subjects: 142
Study: 17725843

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg once a day for 12 weeks)
Number of subjects: 533
Study: 17727882

Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 0
Study: 17761590

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (previously received)
Number of subjects: 15
Study: 17761592

Group type: EXPERIMENTAL
Intervention: Continuous-flow pump implantation
Number of subjects: 133
Study: 17761710

Group type: EXPERIMENTAL
Intervention: Hydralazine (182 mg for rapid acetylators, 83 mg for slow acetylators) and magnesium valproate (40 mg/kg) added to chemotherapy schedule.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydralazine and magnesium valproate intervention.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin, carboplatin, paclitaxel, vinorelbine, gemcitabine, pemetrexed, topotecan, doxorubicin, cyclophosphamide, anastrozole).
Number of subjects: 17
Study: 17765429

Group type: EXPERIMENTAL
Intervention: Nonpreserved intravitreal triamcinolone acetonide in prefilled syringes, injected intravitreally without topical antibiotics prior to injection.
Number of subjects: 839
Study: 17767397

Group type: EXPERIMENTAL
Intervention: Oblimersen in combination with dacarbazine
Number of subjects: 771

Group type: COMPARATOR
Intervention: Dacarbazine alone
Number of subjects: 771
Study: 17767471

Group type: EXPERIMENTAL
Intervention: Lansoprazole treatment for 5 years (median)
Number of subjects: 63
Study: 17784944

Group type: EXPERIMENTAL
Intervention: Transcranial duplex scanning (TCD) of the substantia nigra
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: SPECT scan of the brain
Number of subjects: 250
Study: 17803825

Group type: EXPERIMENTAL
Intervention: Treadmill walking with partial weight support via an overhead harness
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine assisted overground walking
Number of subjects: 130
Study: 17804683

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study: 17804777

Group type: EXPERIMENTAL
Intervention: Electromagnetic needle tracking with CT and US guidance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fusion of tracked US with CT
Number of subjects: 19
Study: 17804851

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17822557

Group type: EXPERIMENTAL
Intervention: Vaccination with HER2 ICD protein-containing dendritic cells (DC) administered intradermally/subcutaneously four times at 3 week intervals.
Number of subjects: 7
Study: 17823147

Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0
Study: 17825712

Group type: EXPERIMENTAL
Intervention: Ad5FGF-4 (alferminogene tadenovec)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study: 17825841

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 17846226

Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (20 mg/m(2)) plus interleukin-12 (IL-12; 300 ng/kg subcutaneously twice weekly) followed by 500 ng/kg subcutaneous IL-12 twice weekly for up to 3 years
Number of subjects: 36
Study: 17854392

Group type: EXPERIMENTAL
Intervention: 1-year outpatient obesity intervention programme based on a high-carbohydrate, fat-reduced diet and increased physical activity
Number of subjects: 44

Group type: COMPARATOR
Intervention: Obese children
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Children with substantial weight loss
Number of subjects: 44
Study: 17869664

Group type: EXPERIMENTAL
Intervention: Traditional Point A (TPA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Estimated brachytherapy dose to APA
Number of subjects: 11
Study: 17875804

Group type: EXPERIMENTAL
Intervention: Combined vaccine of PR1 and WT1 peptides in Montanide adjuvant with granulocyte-macrophage colony-stimulating factor
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined vaccine of PR1 and WT1 peptides
Number of subjects: 8
Study: 17875973

Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with ascending aortic diameters > 2.0 cm/m2 (aortic size index)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with ascending aortic diameters of 3.7 to 4.8 cm and aortic size indices > 2.5 cm/m2
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with aortic size index > 2.0 cm/m2
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Turner syndrome (TS) women with aortic size index >= 2.5 cm/m2
Number of subjects: 166
Study: 17876370

Group type: EXPERIMENTAL
Intervention: Topical acetylcholine chloride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17877652

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 336
Study: 17877830

Group type: EXPERIMENTAL
Intervention: Four-component hospital-based staff communication protocol designed to improve interprofessional collaborative communication.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual communication practices (Control group).
Number of subjects: 20
Study: 17885618

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 96
Study: 17890470

Group type: EXPERIMENTAL
Intervention: Impedance oscillometry (IOS)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Bronchodilation
Number of subjects: 174
Study: 17892636

Group type: EXPERIMENTAL
Intervention: Nonfasting LDLc
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nonfasting non-HDLc
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nonfasting LDLP
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nonfasting DLDLc
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting LDLc
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting DLDLc
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting non-HDLc
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting LDLP
Number of subjects: 31
Study: 17893227

Group type: EXPERIMENTAL
Intervention: 10 mg oral lenalidomide daily
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 10 mg lenalidomide on days 1 to 21 of a 28-day cycle
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 10 mg lenalidomide
Number of subjects: 214
Study: 17896299

Group type: EXPERIMENTAL
Intervention: 2-line gain in visual acuity of the better-seeing eye
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: 2-line loss in visual acuity of the better-seeing eye
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Patients with baseline NEI-VFQ scores > 59.8 and 2-line loss in visual acuity
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Patients with baseline NEI-VFQ scores ≤ 59.8 and 2-line loss in visual acuity
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Overall NEI-VFQ score
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Individual subscale scores
Number of subjects: 828
Study: 17897454

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTi) with sulphadoxine-pyrimethamine (SP) administered 3 times alongside routine vaccinations.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered 3 times alongside routine vaccinations.
Number of subjects: 0
Study: 17897470

Group type: EXPERIMENTAL
Intervention: Active nitric oxide releasing patches
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 100
Study: 17898351

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 100
Study: 17903262

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTX-A) 10 units per Kg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 150
Study: 17905796

Group type: EXPERIMENTAL
Intervention: Bilateral GPi-DBS
Number of subjects: 10
Study: 17906013

Group type: EXPERIMENTAL
Intervention: One-layer closure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two-layer closure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both one- and two-layer closure
Number of subjects: 30
Study: 17909303

Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine patch
Number of subjects: 116
Study: 17910637

Group type: EXPERIMENTAL
Intervention: UCB graft with CD34(+) cell dose
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: UCB graft with CD3(+) cell dose
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: UCB graft with CD34(+)HLADR(+)CD38(+) progenitors
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-resolution matching for HLA-class II (DRB1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: UCB graft with higher cell doses of CD34(+), committed CD34(+) progenitors and CD3(+) T cells
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Early mortality
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Myeloid engraftment
Number of subjects: 31
Study: 17912368

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5g/d) + Conjugated linoleic acid (6g/d)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 17915028

Group type: COMPARATOR
Intervention: Electronic prescribing software with decision support at the point of care; details on dosage and duration not applicable as it is a software intervention.
Number of subjects: 0
Study: 17915977

Group type: EXPERIMENTAL
Intervention: Lamotrigine (dosing ranged from 25 mg every other day to 300 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg/day)
Number of subjects: 24
Study: 17916243

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy within 24 hours of symptom onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic treatment with moxifloxacin followed by delayed elective cholecystectomy
Number of subjects: 0
Study: 17920064

Group type: EXPERIMENTAL
Intervention: Visilizumab 10 microg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Visilizumab 15 microg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Visilizumab
Number of subjects: 32
Study: 17923600

Group type: EXPERIMENTAL
Intervention: Hospice referral
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Older age (per 10-year increment)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Lower serum sodium concentration (per 5-mEq/L increment)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure (per 10-mm Hg increment)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Higher serum urea nitrogen concentration (per 10-mg/dL increment)
Number of subjects: 3010

Group type: EXPERIMENTAL
Intervention: Absence of lipid-lowering drug therapy
Number of subjects: 3010
Study: 17925413

Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) with mean airway pressure increased to 40 cm H2O for 30 seconds
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 26
Study: 17934114

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (AdoMet) levels in patients with lung cancer
Number of subjects: 68

Group type: COMPARATOR
Intervention: S-adenosylmethionine (AdoMet) levels in smokers with benign lung disease
Number of subjects: 68

Group type: COMPARATOR
Intervention: S-adenosylmethionine (AdoMet) levels in healthy nonsmokers
Number of subjects: 68
Study: 17934551

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.d. for 7 weeks
Number of subjects: 3431
Study: 17934748

Group type: EXPERIMENTAL
Intervention: Low-dose mitomycin C (0.01 nM) for 2 weeks followed by 0.1 to 100 microM mitomycin C; P-glycoprotein expression analysis using flow cytometry, immunoblotting, and RT-PCR.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose mitomycin C (0.01 nM) with verapamil (4 microM); P-glycoprotein expression analysis.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (0.1 nM) for 2 weeks; P-glycoprotein expression analysis.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Previous trabeculectomy with mitomycin C; P-glycoprotein expression analysis in surgically removed Tenon tissue.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients not previously exposed to mitomycin C; P-glycoprotein expression analysis.
Number of subjects: 30
Study: 17936715

Group type: EXPERIMENTAL
Intervention: Triple therapy (vitrectomy, intravitreal triamcinolone acetonide injection, and macular laser photocoagulation)
Number of subjects: 24
Study: 17938165

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 92
Study: 17940483

Group type: EXPERIMENTAL
Intervention: Resumption of anticoagulation (n = 103)
Number of subjects: 608

Group type: COMPARATOR
Intervention: No resumption of anticoagulation (n = 120)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Normal D-dimer (n = 385)
Number of subjects: 608
Study: 17942751

Group type: EXPERIMENTAL
Intervention: Clonal expansions of immunoglobulin M (IgM)(+)kappa(+)IgD(low/-)CD21(low)CD27(+) B cells in HCV(+)MC(+) subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antigen selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic B-cell stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypermutated, marginal zone-like IgM(+)CD27(+) B cells
Number of subjects: 0